<DOC>
	<DOCNO>NCT01747850</DOCNO>
	<brief_summary>The purpose study assess Sativex treatment Cannabis dependence . Initially pilot study conduct five subject seek treatment cannabis dependence ensure plan self-titration regimen appropriate use Sativex . This phase open label , placebo control . Then , twelve-week , double-blind , placebo-controlled study male female subject seek treatment cannabis dependence ( n=40 ) . All participant receive combination pharmacotherapy ( Sativex Spray Placebo Spray ) associate weekly intervention combine Motivational Enhancement Therapy Cognitive Behavioral Therapy ( MET/CBT ) . The subject come daily centre ass usage medication . Following medication phase , participant follow-up weekly another four week monthly 6 month follow visit target quit date . The investigator plan enroll 45 subject two-year period .</brief_summary>
	<brief_title>Sativex Behavioral-relapse Prevention Strategy Cannabis Dependence</brief_title>
	<detailed_description>In pilot study subject treat SATIVEX® ( THC/cannabidiol combination buccal spray ) use approach outline randomize control trial . In twelve-week , double-blind , placebo-controlled study visit occur weekly medication phase study . The medication self-titrated three week target quit date set Day 21 . There total 12 week drug exposure . Throughout 12-weeks , participant receive combination pharmacotherapy ( Sativex Spray Placebo Spray ) associate weekly intervention combine Motivational Enhancement Therapy Cognitive Behavioral Therapy ( MET/CBT ) accordance intervention practice show effective treatment cannabis dependence . The intervention adapt Brief Counselling Marijuana Dependence manual publish Substance Abuse Mental Health Services Administration ( SAMHSA ) . At study visit , vital sign self-report rating collect . In addition , subject come daily centre assess medication usage ask provide urine sample ( two time weekly ) blood sample weekly . As may compliance issue , contingency management approach also implement .</detailed_description>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<mesh_term>Peppermint oil</mesh_term>
	<criteria>Adult male female ( gender analyze covariate ) Understand willing comply study requirement restriction Willing use appropriate contraceptive method throughout study Otherwise healthy judge investigator base medical history , physical exam , vitals , ECG labs DSMIV criterion current marijuana dependence Report marijuana primary drug abuse Report use marijuana least 5 day week least one month Have marijuana positive urine drug screen Treatment seek cannabis smoker Smoke le equal equivalent 4 joint per day ( four gram per day participant smoke cannabis form ) Meets DSMIV criterion current axis I disorder include substance use disorder cannabis , nicotine caffeine dependence . Firstdegree relative schizophrenia History seizures History cardiovascular disease History pulmonary disease asthma , COPD Clinically significant pathology oral cavity poor oral hygiene Known sensitivity dronabinol , cannabidiol , propylene glycole , ethanol peppermint oil ( use SATIVEX® buccal spray ) Unstable medical condition Pregnant breastfeed Currently take psychotropic medication benefit illness treatment insomnia , Holding job involves drive , operate heavy machine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>